{"id":"https://openalex.org/W2183683764","doi":null,"title":"Original article Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain","display_name":"Original article Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2183683764","mag":"2183683764"},"language":"en","primary_location":{"id":"mag:2183683764","doi":null,"is_oa":false,"landing_page_url":"https://informahealthcare.com/doi/pdf/10.3111/13696998.2012.726674","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005075798","display_name":"Vivencio Barrios","orcid":"https://orcid.org/0000-0001-6135-7685","observed_orcids":["https://orcid.org/0000-0001-6135-7685"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vivencio Barrios","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6135-7685","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036561737","display_name":"Adalberto Serrano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adalberto Serrano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090246907","display_name":"Max Brosa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Max Brosa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5091664176","display_name":"Margarita Capel","orcid":"https://orcid.org/0000-0001-9431-6302","observed_orcids":["https://orcid.org/0000-0001-9431-6302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Margarita Capel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9431-6302","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":1.0},{"id":"https://openalex.org/keywords/atorvastatin","display_name":"atorvastatin","score":0.9350000023841858},{"id":"https://openalex.org/keywords/generic-statins","display_name":"generic statins","score":0.746999979019165},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9570000171661377},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.7179999947547913},{"id":"https://openalex.org/keywords/high-cardiovascular-risk","display_name":"high cardiovascular risk","score":0.5820000171661377},{"id":"https://openalex.org/keywords/prior-cardiovascular-disease","display_name":"prior cardiovascular disease","score":0.875},{"id":"https://openalex.org/keywords/ldl-cholesterol-targets","display_name":"LDL cholesterol targets","score":0.6200000047683716},{"id":"https://openalex.org/keywords/primary-prevention","display_name":"primary prevention","score":0.5830000042915344},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8510000109672546},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8619999885559082},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.7689999938011169},{"id":"https://openalex.org/keywords/spanish-national-health-system","display_name":"Spanish National Health System","score":0.6729999780654907}],"concepts":[{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.9765461683273315},{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.8604120016098022},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7561843395233154},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.5376376509666443},{"id":"https://openalex.org/C2908737378","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin Calcium","level":3,"score":0.4854479432106018},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.46554434299468994},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40786099433898926},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.12822023034095764}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2183683764","doi":null,"is_oa":false,"landing_page_url":"https://informahealthcare.com/doi/pdf/10.3111/13696998.2012.726674","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1607804102","https://openalex.org/W1839290569","https://openalex.org/W1977628820","https://openalex.org/W1996993842","https://openalex.org/W2013145023","https://openalex.org/W2030499271","https://openalex.org/W2064303441","https://openalex.org/W2064777739","https://openalex.org/W2068685076","https://openalex.org/W2075039728","https://openalex.org/W2136893214","https://openalex.org/W2148463229","https://openalex.org/W2148989961","https://openalex.org/W2154704322","https://openalex.org/W2164089346","https://openalex.org/W2167067204","https://openalex.org/W2169646090","https://openalex.org/W2463322777"],"related_works":["https://openalex.org/W2325992311","https://openalex.org/W2140798021","https://openalex.org/W2905628889","https://openalex.org/W2001963636","https://openalex.org/W2166102918","https://openalex.org/W2545213580","https://openalex.org/W1970295099","https://openalex.org/W71995819","https://openalex.org/W169836971","https://openalex.org/W7095068477"],"abstract_inverted_index":{"Objective:":[0],"The":[1,47,122],"objective":[2],"of":[3,14,23,70,78,87,99,130,162,170,191,196,200,220,231,247,271],"this":[4,201],"study":[5,64,202],"was":[6,93,124,156,186],"to":[7,61,67,95,116,206,213],"carry":[8],"out":[9,126],"a":[10,210],"long-term":[11,214],"cost-effectiveness":[12,255],"analysis":[13,123],"rosuvastatin":[15,79,155,185,238],"compared":[16,58],"with":[17,39,75,136,152,182,234,253],"generic":[18,81,153,243],"atorvastatin":[19,82,244],"in":[20,44,173,176,188,224,245,262,264],"the":[21,51,97,128,131,167,204,218,225,229,258],"treatment":[22,110,222,230],"patients":[24,38,175,181,233],"at":[25,146],"high":[26,235],"cardiovascular":[27,41],"(CV)":[28],"risk":[29,273],"(\ufffd":[30],"5%":[31],"Systematic":[32],"COronary":[33],"Risk":[34],"Evaluation":[35],"[SCORE])":[36],"and":[37,80,106,111,142,193,217,249],"prior":[40,183],"disease":[42],"(CVD)":[43],"Spain.":[45],"Methods:":[46],"efficacy":[48],"data":[49,208],"from":[50,127,209],"Statin":[52],"Therapies":[53],"for":[54,83,114,166],"Elevated":[55],"Lipid":[56],"Levels":[57],"Across":[59],"doses":[60,77],"Rosuvastatin":[62],"(STELLAR)":[63],"were":[65,203],"used":[66,94,261],"simulate":[68],"achievement":[69],"low-density":[71],"lipoprotein":[72],"cholesterol":[73],"targets":[74],"different":[76],"an":[84],"initial":[85,120],"period":[86],"1":[88],"year.":[89,149],"A":[90],"Markov":[91],"model":[92],"estimate":[96],"number":[98],"CV":[100,112,171,236,272],"complications,":[101],"quality-adjusted":[102],"life":[103],"years":[104,118],"(QALYs),":[105],"healthcare":[107],"costs":[108,137],"(lipid-lowering":[109],"events)":[113],"up":[115],"20":[117],"after":[119],"treatment.":[121],"carried":[125],"perspective":[129],"Spanish":[132],"National":[133],"Health":[134],"System,":[135],"(in":[138],"year":[139],"2010":[140],"euros)":[141],"effects":[143],"being":[144],"discounted":[145],"3%":[147],"per":[148,159],"Results:":[150],"Compared":[151],"atorvastatin,":[154],"cost-effective":[157,187],"(cost":[158],"QALY":[160],"gained":[161],"less":[163],"than":[164,242],"E30,000)":[165],"primary":[168],"prevention":[169],"events":[172],"high-risk":[174],"most":[177,194,265],"sub-groups":[178,190,195],"analyzed.":[179],"In":[180],"CVD,":[184],"all":[189],"men":[192],"women.":[197],"Key":[198],"limitations":[199],"need":[205],"extrapolate":[207],"single":[211],"trial":[212],"modeled":[215],"outcomes":[216],"absence":[219],"other":[221],"options":[223],"analysis.":[226],"Conclusions:":[227],"For":[228],"dyslipidemic":[232],"risk,":[237],"is":[239],"more":[240],"effective":[241],"terms":[246],"survival":[248],"quality-of-life":[250],"adjusted":[251],"survival,":[252],"incremental":[254],"ratios":[256],"within":[257],"range":[259],"generally":[260],"Spain,":[263],"sub-populations":[266],"defined":[267],"by":[268],"various":[269],"combinations":[270],"factors.":[274]},"counts_by_year":[],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2016-06-24T00:00:00"}